Hostname: page-component-7c8c6479df-hgkh8 Total loading time: 0 Render date: 2024-03-28T16:41:14.729Z Has data issue: false hasContentIssue false

Brainstem Developmental Venous Anomaly Causing Hemifacial Spasm – Case Report and Review of the Literature

Published online by Cambridge University Press:  02 May 2016

Philippe Rizek
Affiliation:
Department of Clinical Neurological SciencesWestern University, London, Ontario, Canada
Niraj Kumar
Affiliation:
Department of Clinical Neurological SciencesWestern University, London, Ontario, Canada
Manas Sharma
Affiliation:
Department of Medical ImagingWestern UniversityLondon, Ontario, Canada
Mandar Jog
Affiliation:
Department of Clinical Neurological SciencesWestern University, London, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

Type
Letters to the Editor
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2016 

Hemifacial spasm (HFS) is considered to be a form of segmental myoclonus of muscles innervated by the facial nerve (CN VII), with unilateral twitching beginning in the orbicularis oculi, and spreading to the other ipsilateral muscles of facial expression over several years. Over time, patients may present with sustained or tonic contractions.Reference Lu, Yeung, Gerrard, Michaelides, Sekula and Bulsara 1 The prevalence of HFS is 14.5 per 100,000 women and 7.4 per 100,000 men, with an average age of onset of 44 years.Reference Lu, Yeung, Gerrard, Michaelides, Sekula and Bulsara 1 , Reference Chaudhry, Srivastava and Joshi 2 Primary HFS is triggered by vascular compression whereas secondary HFS comprises all other causes of CN VII damage, thus, magnetic resonance imaging is recommended in all patients with HFS.Reference Glocker, Krauss, Deuschl, Seeger and Lucking 3 Primary HFS most commonly occurs secondary to arterial compression of the CN VII at the root exit zone (REZ).Reference Campos-Benitez and Kaufmann 4 Venous compression is rare.Reference Campos-Benitez and Kaufmann 4 - Reference Jannetta 6 Secondary causes include brainstem tumours, stroke, demyelinating plaques, trauma or Bell’s palsy.Reference Campos-Benitez and Kaufmann 4 We describe a rare case of HFS associated with a pontine developmental venous anomaly (DVA).

A 32 year-old otherwise healthy woman presented with left HFS since the age of five years. The spontaneous twitching initially involved the left eye; subsequently progressing to become tonic spasms of the left face and anterior neck over several years. These were exacerbated by voluntary facial movements and stress; eventually increasing in frequency and persisting for a longer duration, lasting over one minute (Video 1). There were no speech changes, ocular deviation or other abnormal movements. The remainder of her neurological examination was normal. Electroencephalogram (EEG) was normal. Magnetic resonance imaging brain showed a DVA in the left pons in proximity to the left CN VII REZ (Figure 1). Carbamazepine and phenytoin were tried, but discontinued early due to adverse reactions (flu-like illness and vomiting, respectively). She responded to botulinum toxin (onabotulinumtoxinA) injections in the affected left facial muscles.

Figure 1 Two selected images from axial post-contrast 3D T1 MRI sequence acquisition show a tuft of tributary veins, or “caput medusae” (A, arrow), consistent with a developmental venous anomalyReference Ruíz, Yilmaz and Gailloud 14 , in the left posterior pons near the fourth ventricle leading to the larger draining abnormal vein (B, arrowhead) which is seen apposed to the left 7th cranial nerve in its root exit zone in the cerebellopontine angle cistern. There was no infarction, hemorrhage, mass or other relevant finding on the study.

Hemifacial spasm is thought to result from hyperexcitability of the CN VII nucleus due to antidromic feedback from peripheral lesions compressing the nerve or ephaptic transmission within the proximal segment of CN VII, leading to excessive firing.Reference Chaudhry, Srivastava and Joshi 2 Hemifacial spasm is most commonly caused by vascular compression of CN VII by the anterior inferior cerebellar artery (43%), posterior inferior cerebellar artery (31%), vertebral artery (23%), or a large vein (3%).Reference Campos-Benitez and Kaufmann 4 , Reference Wang, Thirumala and Shah 5 Untreated, HFS can lead to social embarrassment and, in severe cases, involuntary eye closure may interfere with vision.Reference Chaudhry, Srivastava and Joshi 2 The prognosis depends on treatment selection and response. Anticonvulsants, such as carbamazepine, may be tried with variable efficacy (level U) and limited by side effects, such as sleepiness, headaches, dizziness and ataxia.Reference Chaudhry, Srivastava and Joshi 2 The response to anticonvulsants in certain cases of HFS may suggest another pathophysiological mechanism.

Microvascular decompression (MVD) has been shown to be effective in 84-98% of primary HFS patients (level C)Reference Campos-Benitez and Kaufmann 4 , Reference Zhu, Li and Zhong 7 ; with delayed response in 25.4%Reference Xia, Zhong, Zhu, Dou, Liu and Li 8 , sometimes taking up to three years for resolution of symptoms.Reference Jo, Kong and Park 9 Recurrence may develop in 10.3% of patients within two years.Reference Zhu, Li and Zhong 7 Causes of failed MVD may be related to missing the offending vessel, not detaching all offending vessels, or related to a difficult surgical approach.Reference Zhong, Li and Zhu 10 Intraoperative electromyography monitoring over the mentalis, looking for the reduction or elimination of the abnormal muscle response may help increase the success of MVD.Reference Zhu, Li and Zhong 7 Although repeat MVD may be required with good reported successReference Xia, Zhong, Zhu, Dou, Liu and Li 8 , this puts patients again at risk of surgical complications, including hearing loss, facial palsy, ataxia, cerebrospinal fluid leakage, diplopia, headache, wound infection, and vertigo.Reference Miller and Miller 11 , Reference Wang, Thirumala and Shah 12 Due to these surgical risks, delayed response, and occasional difficulty in identifying a culprit vessel, botulinum toxin may be used as first line for HFS. Microvascular decompression may be performed after failed treatment with botulinum toxin.Reference Miller and Miller 11 , Reference Wang, Thirumala and Shah 12

A recent study of 15 patients (mean 52.8 years) suggests that patients with HFS associated with venous compression show a higher incidence of neck (platysma muscle) involvement and tonic contraction (tonus) of the facial musclesReference Wang, Thirumala and Shah 5 , as seen in our patient. Infratentorial veins may be the primary or secondary offending vessel in HFS. Female sex and venous involvement have been associated with recurrence of HFS after MVD.Reference Wang, Thirumala and Shah 5 This may be related to location or severity of compression.

There are very few cases of HFS due to DVA reported in the literature (Table 1). Developmental venous anomalies, also known as venous angiomas, are congenital benign anatomic variants which account for over 60% of cerebral vascular malformations; with very low risk for bleeding or for causing symptoms, unless associated with a cavernous malformation.Reference Chiaramonte, Bonfiglio, Amore and Chiaramonte 13 Typically, neurosurgical manipulation of DVAs is generally avoided, due to their relatively benign nature and vital role in drainage of normal brain tissue, fragility and risk of venous infarction from manipulation.Reference Ruíz, Yilmaz and Gailloud 14 , Reference Chen, Lee and Lui 15 There is minimal literature on MVD for DVAs associated with HFS, with resolution of HFS symptoms in twoReference Chen, Lee and Lui 15 , Reference Mahran, Samii, Penkert and Ostertag 16 of the three reported cases; without long-term post-operative followup.Reference Chen, Lee and Lui 15 - Reference Arita, Kishima and Hosomi 17 Botulinum toxin is thus a reasonable option for symptomatic treatment of HFS associated with isolated DVA, as selected for our patient.

Table 1 Reported cases in the literature of HFS associated with DVA.

CBZ: carbamazepine; DVA: developmental venous anomaly; F: female; HFS: hemifacial spasm; M: male; CN: cranial nerve; REZ: root exit zone; IAC: internal auditory canal.

Of the commercially available formulations of botulinum toxin in Canada, evidence supports a level B recommendation for onabotulinumtoxinA, and a level U recommendation for incobotulinumtoxinA for the symptomatic treatment of HFS.Reference Hallett, Albanese and Dressler 18 The latency of improvement after botulinum toxin injections in HFS is between 2-14 days, with mean duration of improvement of 15.7 weeks, and 85% improvement in spasms, as reported by patients.Reference Sorgun, Yilmaz, Akin, Mercan and Akbostanci 19 Side effects are transient and most commonly include mild ptosis (mean: 24%) and facial weakness (mean: 27%).Reference Sorgun, Yilmaz, Akin, Mercan and Akbostanci 19

Our patient is the youngest reported case of HFS associated with isolated pontine DVA with symptoms presenting in childhood. Because the complication rate and recurrence risk is high for MVD of veins associated with HFS, botulinum toxin may be a reasonable treatment to offer such patients.

P Rizek, N Kumar, and M Sharma report no disclosures relevant to manuscript. M Jog has received consulting fees as an advisor for Abbvie Canada, Allergan and Merz Pharma Canada. He has obtained research support from Merz, Allergan, CIHR, Mitacs, AMOSO and the Age-Well Network of Centers of Excellence (NCE) of Canada program.

Statement of Authorship

P Rizek – Study concept, design, writing of the first draft and revision of the manuscript. N Kumar – Study concept and design. M Sharma – Selection of imaging and interpretation. M Jog – Study supervision, revision and critique of the manuscript.

Supplementary Material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/cjn.2016.33

References

1. Lu, AY, Yeung, JT, Gerrard, JL, Michaelides, EM, Sekula, RF, Bulsara, KR. Hemifacial spasm and neurovascular compression. Sci World J. 2014;2014:349319.CrossRefGoogle ScholarPubMed
2. Chaudhry, N, Srivastava, A, Joshi, L. Hemifacial spasm: The past, present and future. J Neurol Sci. 2015;356:27-31.CrossRefGoogle ScholarPubMed
3. Glocker, FX, Krauss, JK, Deuschl, G, Seeger, W, Lucking, CH. Hemifacial spasm due to posterior fossa tumors: the impact of tumor location on electrophysiological findings. Clin Neurol Neurosurg. 1998;10:104-111.10.1016/S0303-8467(98)00026-2CrossRefGoogle Scholar
4. Campos-Benitez, M, Kaufmann, AM. Neurovascular compression findings in hemifacial spasm. J Neurosurg. 2008;109:416-420.CrossRefGoogle ScholarPubMed
5. Wang, X, Thirumala, P, Shah, A. The role of vein in microvascular decompression for hemifacial spasm: a clinical analysis of 15 cases. Neurol Res. 2013:389-394.CrossRefGoogle ScholarPubMed
6. Jannetta, PJ. Hemifacial spasm caused by a venule: case report. Neurosurgery. 1984;14(1):89-92.10.1227/00006123-198401000-00021CrossRefGoogle ScholarPubMed
7. Zhu, J, Li, S-T, Zhong, J, et al. Role of arterioles in management of microvascular decompression in patients with hemifacial spasm. J Clin Neurosci. 2012;19:375-379.CrossRefGoogle ScholarPubMed
8. Xia, L, Zhong, J, Zhu, J, Dou, N-N, Liu, M-X, Li, S-T. Delayed Relief of Hemifacial Spasm After Microvascular Decompression. J Craniofac Surg. 2015;26:408-410.CrossRefGoogle ScholarPubMed
9. Jo, KW, Kong, D-S, Park, K. Microvascular decompression for hemifacial spasm: long-term outcome and prognostic factors, with emphasis on delayed cure. Neurosurg Rev. 2013;36:297-301; discussion 301-2.CrossRefGoogle ScholarPubMed
10. Zhong, J, Li, ST, Zhu, J, et al. A clinical analysis on microvascular decompression surgery in a series of 3000 cases. Clin Neurol Neurosurg. 2012;114:846-851.CrossRefGoogle Scholar
11. Miller, LE, Miller, VM. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg. 2012;26:438-444.10.3109/02688697.2011.641613CrossRefGoogle ScholarPubMed
12. Wang, X, Thirumala, PD, Shah, A, et al. Effect of previous botulinum neurotoxin treatment on microvascular decompression for hemifacial spasm. Neurosurg Focus. 2013;34:E3.10.3171/2012.11.FOCUS12373CrossRefGoogle ScholarPubMed
13. Chiaramonte, R, Bonfiglio, M, Amore, AD, Chiaramonte, I. Developmental Venous Anomaly Responsible for Hemifacial Spasm. Neuroradiol J. 2013:201-207.CrossRefGoogle ScholarPubMed
14. Ruíz, DSM, Yilmaz, H, Gailloud, P. Cerebral developmental venous anomalies: current concepts. Ann Neurol. 2009;66(3):271-283.CrossRefGoogle ScholarPubMed
15. Chen, HJ, Lee, TC, Lui, CC. Hemifacial spasm caused by a venous angioma. Case report. J Neurosurg. 1996;85:716-717.CrossRefGoogle ScholarPubMed
16. Mahran, A, Samii, M, Penkert, G, Ostertag, H. Vascular lesions of the internal auditory canal. Skull Base Surg. 1991;1:78-84.CrossRefGoogle ScholarPubMed
17. Arita, H, Kishima, H, Hosomi, K, et al. Hemifacial spasm caused by intra-axial brainstem cavernous angioma with venous angiomas. Br J Neurosurg. 2012;26:281-283.10.3109/02688697.2011.609605CrossRefGoogle ScholarPubMed
18. Hallett, M, Albanese, A, Dressler, D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114.CrossRefGoogle ScholarPubMed
19. Sorgun, MH, Yilmaz, R, Akin, YA, Mercan, FN, Akbostanci, MC. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years. J Clin Neurosci. 2015;22:1319-1325.CrossRefGoogle ScholarPubMed
Figure 0

Figure 1 Two selected images from axial post-contrast 3D T1 MRI sequence acquisition show a tuft of tributary veins, or “caput medusae” (A, arrow), consistent with a developmental venous anomaly14, in the left posterior pons near the fourth ventricle leading to the larger draining abnormal vein (B, arrowhead) which is seen apposed to the left 7th cranial nerve in its root exit zone in the cerebellopontine angle cistern. There was no infarction, hemorrhage, mass or other relevant finding on the study.

Figure 1

Table 1 Reported cases in the literature of HFS associated with DVA.

Rizek supplementary material

Video

Download Rizek supplementary material(Video)
Video 9.2 MB